Economic impact of prior authorization policies for atypical antipsychotics in the treatment of schizophrenia

Population Health Management

Volumn 13, Issue 5, 2010, Pages 247-254

  Abouzaid, Safiya ^a   Jutkowitz, Eric ^a   Foley, Kathy A ^a   Pizzi, Laura T ^a   Kim, Edward ^b   Bates, Jay ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ANALYTICAL RESEARCH; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; COST CONTROL; COST OF ILLNESS; DRUG COST; HEALTH CARE COST; HEALTH CARE POLICY; HOSPITALIZATION; HUMAN; MEDICAID; PRESCRIPTIVE AUTHORITY; PRIOR AUTHORIZATION POLICY; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; COST SAVINGS; DECISION TREES; HEALTH CARE COSTS; HUMANS; INSURANCE CLAIM REVIEW; INSURANCE, PHARMACEUTICAL SERVICES; MEDICAID; MONTE CARLO METHOD; ORGANIZATIONAL POLICY; PROBABILITY; SCHIZOPHRENIA; UNITED STATES;

EID: 77957726331     PISSN: 19427891     EISSN: 19427905     Source Type: Journal    
DOI: 10.1089/pop.2009.0063     Document Type: Article

References (27)

1. Truffer C, Klemm J, Hoffman E, Wolf C. 2008 Actuarial Report on the Financial Outlook for Medicaid. Washington, DC: Office of the Actuary, Centers for Medicare & Medicaid Services, United States Department of Health & Human Services; 2008.
2. Kaiser Family Foundation. Prescription drug trends. Available at: http://www.kff.org/rxdrugs/upload/3057-07.pdf.
3. Lied TR, Gonzalez J, Taparanskas W, Shukla T. Trends and current drug utilization patterns of medicaid beneficiaries. Health Care Financ Rev 2006;27:123-132.
4. Soumerai SB. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Aff (Millwood) 2004;23:135-146.
5. Huskamp HA. Managing psychotropic drug costs: Will formularies work? Health Aff (Millwood) 2003;22:84-96.
6. Phillips CR, Larson LN. Evaluating the operational performance and financial effects of a drug prior authorization program. J Managed Care Pharm 1997;3:699-706.
7. Smith V, Gifford K, Ellis E, Rudowitz R, O'Malley M, Marks C. Headed for a Crunch: An Update on Medicaid Spending, Coverage and Policy Heading into an Economic Downturn. Washington, DC: Kaiser Commission on Medicaid and the Uninsured, Kaiser Family Foundation; 2008.
8. Koyanagi C, Forquer S, Alfano E. Medicaid policies to contain psychiatric drug costs. Health Aff (Millwood) 2005;24:536-544.
9. Law MR, Ross-Degnan D, Soumerai SB. Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements. Psychiatr Serv 2001; 59:540-546.
10. Smalley WE, Griffin MR, Fought RL, Sullivan L, Ray WA. Effect of a prior-authorization requirement on the use of nonsteroidal antiinflammatory drugs by Medicaid patients. N Engl J Med 1995;332:1612-1617.
11. Fischer MA, Schneeweiss S, Avorn J, Solomon DH. Medicaid prior-authorization programs and the use of cycloox-ygenase-2 inhibitors. N Engl J Med 2004;351:2187-2194.
12. Delate T, Mager DE, Sheth J, Motheral BR. Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization program in a Medicaid population. Am J Manag Car 2005;11:29-36.
13. Soumerai SB, Zhang F, Ross-Degnan D, et al. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Health Aff (Millwood) 2008;27:185-195.
14. Law MR, Soumerai SB, Ross-Degnan D, Adams AS. A longitudinal study of medication nonadherence and hospi-talization risk in schizophrenia. J Clin Psychiatry 2008;69:47-53.
15. Gitlin M, Nuechterlein K, Subotnik KL, et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 2001;158:1835-1842.
16. Marcus SC, Olfson M. Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr Bull 2008;34:173-180.
17. Rabinowitz J, Lichtenberg P, Kaplan Z, Mark M, Nahon D, Davidson M. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risper-idone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001;158:266-269.
18. Treur M, Heeg B, Moller HJ, Schmeding A, van Hout B. A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss. BMC Health Serv Res 2009;9:32.
19. LaPensee KT. Analysis of a prescription drug prior authorization program in a Medicaid health maintenance organization. J Manag Care Pharm 2003;9:36-44.
20. Moeller KE, Shireman TI, Liskow BI. Relapse rates in patients with schizophrenia receiving aripiprazole in comparison with other atypical antipsychotics. J Clin Psychiatry 2006;67:1942-1947.
21. IMS Health. Available at: http://www.imshealth.com/portal/site/imshealth. Accessed February 9, 2009.
22. MICROMEDEX® Healthcare Series. MICROMEDEX. Available at: http://www.thomsonhc.com/hcs/librarian. Accessed April 29, 2009.
23. Drugstore.com. Risperdal. Available at: http://www.drugstore.com/ qxn50458032006-333181-sespider/risperdal/risperdal.htm. Accessed April 14, 2009.
24. Crown WH, Neslusan C, Russo PA, Holzer S, Ozminkowski R, Croghan T. Hospitalization and total medical costs for privately insured persons with schizophrenia. Adm Policy Ment Health 2001;28:335-351.
25. Farley JF, Cline RR, Schommer JC, Hadsall RS, Nyman JA. Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications. Clin Ther 2008;30:1524, 1539; discussion 1506-1507.
26. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56:241-247. (Pubitemid 29125132)
27. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Anti-psychotic Trials of Intervention Effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223.